ArticleFrontiers in immunology2025
Deep learning-based multimodal approach for non-invasive prediction and prognostic analysis of immune and angiogenic biomarkers in extrahepatic cholangiocarcinoma.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to develop a deep learning (DL)-based multimodal framework that integrates magnetic resonance imaging (MRI), clinical, and laboratory data to predict programmed death ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF) expression in Extrahepatic cholangiocarcinoma (eCCA) patients and assess the prognostic value. Methods: A retrospective cohort study involving 96 patients with eCCA was conducted across two institutions. A total of 16050 raw MRI images (11505 T1WI, 2371 T2WI, 2372 DWI) and 1570 tumor-containing images (990 T1WI, 289 T2WI, 291 DWI) were analyzed. Radiomic feature extraction was performed manually segmented tumor regions from MRI scans. The multimodal DL framework integrated DL features extracted from images and radiomic features as well as clinical-laboratory features through a repeated attention mechanism. Prognostic stratification was performed using Cox regression analysis to predict overall survival (OS) and evaluate the clinical utility of the model. Results: The DL framework demonstrated moderate predictive performance for PD-L1 expression (AUC = 0.71) and good predictive capability for VEGF expression (AUC = 0.85) in the test cohort. The combination of DL-based imaging features and radiomic data outperformed single-modality approaches. Prognostic analysis revealed significant associations of model-predicted PD-L1 and VEGF expression with OS in eCCA patients. The Cox model-based nomogram demonstrated significant survival stratification (p = 0.006), with performance comparable to traditional immunohistochemistry-based methods. Conclusion: Our findings highlighted the potential of integrating DL and radiomics for non-invasive, preoperative biomarker profiling, offering a promising tool for personalized treatment strategies and improved clinical decision-making in eCCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.